Bioheart Financial Statements
Bioheart Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
This data is provided as per license from EDGAR Online
Bioheart Income Statement
| 2007 | 2006 | 2005 | |
|---|---|---|---|
| Revenue ($ mil.) | 0.3 | 0.1 | 0.1 |
| Gross Profit ($ mil.) | 0.2 | -- | 0.0 |
| Operating Income ($ mil.) | (14.7) | -- | (7.4) |
| Total Net Income ($ mil.) | (18.1) | (13.2) | (7.3) |
| Diluted EPS (Net Income) | (1.37) | -- | -- |
Bioheart Stock Quote & Chart
05/13/08 12:13:32 EST •
NASDAQ •
3.14
•
 -0.3200
•
-9.2486 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
Bioheart Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 172.73 | 1.54 | 1.70 |
| Price/Earnings Ratio | -- | 21.98 | 16.30 |
| Price/Book Ratio | -- | 2.62 | 1.60 |
| Price/Cash Flow Ratio | -- | 14.64 | 10.36 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Bioheart Financial Ratios
Bioheart Competitive Intelligence
| Advanced Cell Technology | Baxter | MG Biotherapeutics | |
|---|---|---|---|
| Annual Sales ($ mil.) | 0.6 | 11,263.0 | 4.0 |
| Employees | -- | 46,000 | 50 |
| Market Cap ($ mil.) | -- | 39,741.8 | -- |
Competitive Landscape
